India's (Pharmacy of the World) Status At Risk: Insight’s From Letter to PM Modi by Analysts at Sanford Bernstein

▴ Insight’s From Letter to PM Modi by Analysts at Sanford Bernstein
Despite its potential, India does not feature prominently in the global healthcare innovation index or patent publications.

India has long been hailed as the “pharmacy of the world” and the “vaccine workshop of the world,” supplying cost-effective medicines to millions globally. However, in recent years, India's position in the global biopharma sector has faced growing challenges compared to its Asian counterparts. According to leading healthcare analysts at Sanford Bernstein, India needs to recalibrate its strategy to become a powerhouse of innovation in the biopharma domain. In an open letter addressed to Prime Minister Narendra Modi, experts Nithya Balasubramanian and Parth Shah highlighted several areas where India is lagging behind its peers.

While India boasts a strong generic drugs and vaccines industry, providing affordable medicines to millions worldwide, it falls short in various aspects of innovation and manufacturing. One concerning aspect is India's low public health expenditure, accounting for only 3 percent of GDP and declining since 2014. On the other hand, countries like Brazil and Mexico allocate a higher budget to healthcare, indicating a need for increased investment in public health infrastructure.

Manufacturing capacity in biopharma is another area of concern. Chinese and Korean companies have made significant investments in biomanufacturing, outpacing India's efforts in this field. Moreover, China has emerged as a global biotech hub, with substantial investments and a strong talent pool driving innovation. South Korea is also catching up, with several biotech start-ups making their mark in global markets.

In terms of drug innovation, India faces significant challenges. Despite its potential, India does not feature prominently in the global healthcare innovation index or patent publications. Less than 2 percent of drugs under development are from India, indicating a lack of investment in innovative research and development. The economic viability of innovative drugs is a concern for pharmaceutical companies, given the limited pricing power in India's market.

To address these challenges, India must focus on creating a conducive environment for biopharma innovation. This includes investing in research talent, attracting skilled professionals back to India, and providing adequate funding for biotech start-ups. Regulatory standards for manufacturing and clinical trials need to be harmonized to streamline the innovation process. Additionally, schemes like Production Linked Incentives (PLI) should be extended to biomanufacturing to level the playing field with Asian peers.

Despite these challenges, India remains a key player in the global pharmaceutical industry. The country's domestic market is home to thousands of manufacturers, supplying affordable medicines to millions of patients worldwide. India has earned the title of the 'pharmacy of the world' and the 'vaccine workshop of the world,' highlighting its crucial role in healthcare provision. Moreover, Indian companies dominate the generic drugs market in the US, showcasing their significance in the global pharmaceutical landscape.

In conclusion, while India faces challenges in biopharma innovation, there are ample opportunities for growth and development. By investing in research, talent, and regulatory reforms, India can enhance its position as a leader in the global biopharma sector. With the right strategies and policies in place, India can unlock its full potential and contribute to healthcare innovation on a global scale.

Tags : #

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026